BioAtla, Inc

BCABNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

1.66M

on 2026-06-30, from 962K on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-50 reverse split; each bar's tip shows the count as filed.

a raise that quarter, at its price

Newest

$200.0M

S-3 of 2026-01-16. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$3.8M

Agreement of 2026-01-16. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-13 is not read yet.

Cash

0.3 quarters

$1.5M on 2026-06-30 ÷ $5.9M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-11-20	Public offering	243,428	not read	not read	424B5 ↗

Also on file: a 1-for-5 reverse split, 2026-01-09 8-K ↗